CLEIA CA125 evidences: Good analytical performance avoiding "hook effect"

R. Falzarano, V. Viggiani, S. Michienzi, B. Colaprisca, F. Longo, L. Frati, E. Anastasi

Research output: Contribution to journalArticle

Abstract

Cancer antigen 125 (CA125) is a coelomic epithelium-related antigen carried by a high molecular weight glycoprotein complex. It is commonly used as a tumor marker for ovarian cancer to monitor disease progression and response to therapy and as an early detection for recurrence after treatment. The aim of this study was to test the reliability of two different assay methods, a radioimmunometric assay (RIA) and an automated chemiluminescent enzyme immunoassay (CLEIA) system, by measuring CA125 serum levels using both methods in 357 patients and comparing the results. Patients were recruited from Oncologic Unit A, Policlinico Umberto I, Roma. Eighty-six were healthy donors, while 271 were oncologic patients representing a variety of diagnoses. Within this group, 76 patients were diagnosed with an ovarian related pathology (28 cancerous and 48 benign). The evaluation of CA125 marker blood levels showed a high agreement in healthy donors group (R 2 = 0.9003). Interesting results emerged when sera collected from oncologic patients were assessed: significant differences between the two assays were found in nine samples. When assayed again with RIA after a dilution, new values agreed with undiluted CLEIA values (R 2 = 0.9847). Our data suggest an overall good comparison between the two methods. However, some artifacts were obtained with RIA and indicate an underlying presence of "hook effect". CLEIA automated assay showed a good reliability and should be preferred to one-step radioimmunoassays in order to minimize errors.

Original languageEnglish
Pages (from-to)387-393
Number of pages7
JournalTumor Biology
Volume34
Issue number1
DOIs
Publication statusPublished - Feb 2013

Fingerprint

Immunoenzyme Techniques
Antigens
Neoplasms
Tissue Donors
Luminescent Measurements
Differentiation Antigens
Tumor Biomarkers
Serum
Ovarian Neoplasms
Artifacts
Radioimmunoassay
Disease Progression
Glycoproteins
Epithelium
Molecular Weight
Pathology
Recurrence
Therapeutics

Keywords

  • CA125 biomarker
  • Chemiluminescence system
  • Radioimmunoassay

ASJC Scopus subject areas

  • Cancer Research

Cite this

Falzarano, R., Viggiani, V., Michienzi, S., Colaprisca, B., Longo, F., Frati, L., & Anastasi, E. (2013). CLEIA CA125 evidences: Good analytical performance avoiding "hook effect". Tumor Biology, 34(1), 387-393. https://doi.org/10.1007/s13277-012-0561-6

CLEIA CA125 evidences : Good analytical performance avoiding "hook effect". / Falzarano, R.; Viggiani, V.; Michienzi, S.; Colaprisca, B.; Longo, F.; Frati, L.; Anastasi, E.

In: Tumor Biology, Vol. 34, No. 1, 02.2013, p. 387-393.

Research output: Contribution to journalArticle

Falzarano, R, Viggiani, V, Michienzi, S, Colaprisca, B, Longo, F, Frati, L & Anastasi, E 2013, 'CLEIA CA125 evidences: Good analytical performance avoiding "hook effect"', Tumor Biology, vol. 34, no. 1, pp. 387-393. https://doi.org/10.1007/s13277-012-0561-6
Falzarano R, Viggiani V, Michienzi S, Colaprisca B, Longo F, Frati L et al. CLEIA CA125 evidences: Good analytical performance avoiding "hook effect". Tumor Biology. 2013 Feb;34(1):387-393. https://doi.org/10.1007/s13277-012-0561-6
Falzarano, R. ; Viggiani, V. ; Michienzi, S. ; Colaprisca, B. ; Longo, F. ; Frati, L. ; Anastasi, E. / CLEIA CA125 evidences : Good analytical performance avoiding "hook effect". In: Tumor Biology. 2013 ; Vol. 34, No. 1. pp. 387-393.
@article{7e5ca361f2e24ef0b48642aa98a4db77,
title = "CLEIA CA125 evidences: Good analytical performance avoiding {"}hook effect{"}",
abstract = "Cancer antigen 125 (CA125) is a coelomic epithelium-related antigen carried by a high molecular weight glycoprotein complex. It is commonly used as a tumor marker for ovarian cancer to monitor disease progression and response to therapy and as an early detection for recurrence after treatment. The aim of this study was to test the reliability of two different assay methods, a radioimmunometric assay (RIA) and an automated chemiluminescent enzyme immunoassay (CLEIA) system, by measuring CA125 serum levels using both methods in 357 patients and comparing the results. Patients were recruited from Oncologic Unit A, Policlinico Umberto I, Roma. Eighty-six were healthy donors, while 271 were oncologic patients representing a variety of diagnoses. Within this group, 76 patients were diagnosed with an ovarian related pathology (28 cancerous and 48 benign). The evaluation of CA125 marker blood levels showed a high agreement in healthy donors group (R 2 = 0.9003). Interesting results emerged when sera collected from oncologic patients were assessed: significant differences between the two assays were found in nine samples. When assayed again with RIA after a dilution, new values agreed with undiluted CLEIA values (R 2 = 0.9847). Our data suggest an overall good comparison between the two methods. However, some artifacts were obtained with RIA and indicate an underlying presence of {"}hook effect{"}. CLEIA automated assay showed a good reliability and should be preferred to one-step radioimmunoassays in order to minimize errors.",
keywords = "CA125 biomarker, Chemiluminescence system, Radioimmunoassay",
author = "R. Falzarano and V. Viggiani and S. Michienzi and B. Colaprisca and F. Longo and L. Frati and E. Anastasi",
year = "2013",
month = "2",
doi = "10.1007/s13277-012-0561-6",
language = "English",
volume = "34",
pages = "387--393",
journal = "Tumor Biology",
issn = "1010-4283",
publisher = "Springer Netherlands",
number = "1",

}

TY - JOUR

T1 - CLEIA CA125 evidences

T2 - Good analytical performance avoiding "hook effect"

AU - Falzarano, R.

AU - Viggiani, V.

AU - Michienzi, S.

AU - Colaprisca, B.

AU - Longo, F.

AU - Frati, L.

AU - Anastasi, E.

PY - 2013/2

Y1 - 2013/2

N2 - Cancer antigen 125 (CA125) is a coelomic epithelium-related antigen carried by a high molecular weight glycoprotein complex. It is commonly used as a tumor marker for ovarian cancer to monitor disease progression and response to therapy and as an early detection for recurrence after treatment. The aim of this study was to test the reliability of two different assay methods, a radioimmunometric assay (RIA) and an automated chemiluminescent enzyme immunoassay (CLEIA) system, by measuring CA125 serum levels using both methods in 357 patients and comparing the results. Patients were recruited from Oncologic Unit A, Policlinico Umberto I, Roma. Eighty-six were healthy donors, while 271 were oncologic patients representing a variety of diagnoses. Within this group, 76 patients were diagnosed with an ovarian related pathology (28 cancerous and 48 benign). The evaluation of CA125 marker blood levels showed a high agreement in healthy donors group (R 2 = 0.9003). Interesting results emerged when sera collected from oncologic patients were assessed: significant differences between the two assays were found in nine samples. When assayed again with RIA after a dilution, new values agreed with undiluted CLEIA values (R 2 = 0.9847). Our data suggest an overall good comparison between the two methods. However, some artifacts were obtained with RIA and indicate an underlying presence of "hook effect". CLEIA automated assay showed a good reliability and should be preferred to one-step radioimmunoassays in order to minimize errors.

AB - Cancer antigen 125 (CA125) is a coelomic epithelium-related antigen carried by a high molecular weight glycoprotein complex. It is commonly used as a tumor marker for ovarian cancer to monitor disease progression and response to therapy and as an early detection for recurrence after treatment. The aim of this study was to test the reliability of two different assay methods, a radioimmunometric assay (RIA) and an automated chemiluminescent enzyme immunoassay (CLEIA) system, by measuring CA125 serum levels using both methods in 357 patients and comparing the results. Patients were recruited from Oncologic Unit A, Policlinico Umberto I, Roma. Eighty-six were healthy donors, while 271 were oncologic patients representing a variety of diagnoses. Within this group, 76 patients were diagnosed with an ovarian related pathology (28 cancerous and 48 benign). The evaluation of CA125 marker blood levels showed a high agreement in healthy donors group (R 2 = 0.9003). Interesting results emerged when sera collected from oncologic patients were assessed: significant differences between the two assays were found in nine samples. When assayed again with RIA after a dilution, new values agreed with undiluted CLEIA values (R 2 = 0.9847). Our data suggest an overall good comparison between the two methods. However, some artifacts were obtained with RIA and indicate an underlying presence of "hook effect". CLEIA automated assay showed a good reliability and should be preferred to one-step radioimmunoassays in order to minimize errors.

KW - CA125 biomarker

KW - Chemiluminescence system

KW - Radioimmunoassay

UR - http://www.scopus.com/inward/record.url?scp=84872761625&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872761625&partnerID=8YFLogxK

U2 - 10.1007/s13277-012-0561-6

DO - 10.1007/s13277-012-0561-6

M3 - Article

C2 - 23111756

AN - SCOPUS:84872761625

VL - 34

SP - 387

EP - 393

JO - Tumor Biology

JF - Tumor Biology

SN - 1010-4283

IS - 1

ER -